CDX 101
Alternative Names: CDX-101Latest Information Update: 28 Nov 2025
At a glance
- Originator Cardax Pharmaceuticals
- Class Anti-inflammatories; Antihyperlipidaemics; Cardiovascular therapies
- Mechanism of Action Antioxidants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Dyslipidaemias; Hypertriglyceridaemia
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (PO)
- 28 Nov 2025 No recent reports of development identified for preclinical development in Dyslipidaemias in USA (PO)
- 01 Oct 2021 CDX 101 is available for licensing as of 01 Oct 2021. https://cardaxpharma.com/cdx-101/ (Cardax Pharmaceuticals pipeline, October 2021)